FDA Submissions and Lifecycle Management
After an initial IND application is authorized by the FDA (also called receiving the “may proceed”) or an initial IDE application is approved by the FDA, the Sponsor is required to maintain a current application with the FDA. This section outlines ongoing and the final submission requirements. Refer to the WI Submitting to the FDA for details on how to submit. OCR Regulatory can assist you with templates, planners, and submission support. Please contact us at PSOM-IND-IDE@POBOX.upenn.edu.
For some studies, an individual might be both the PI and the (Regulatory) Sponsor. In this case, both sets of responsibilities mentioned apply.
Electronic submission is the preferred method for FDA IND submissions and a FDA form 1571 is always required (Form FDA 1571 and instructions).1 Secure email communications with the FDA require use of PennMedicine email accounts.
The types of submissions required after the IND Application is authorized are summarized below2 in the table, and more information can be found on the FDA Investigator-Initiated IND Applications webpage. Please contact OCR Regulatory for additional guidance via email at PSOM-IND-IDE@POBOX.upenn.edu.
IND Submissions2,3 |
Description of Submission | Submission and/or Implementation Requirement Timeline |
---|---|---|
Protocol Amendment – New Protocol |
When a sponsor intends to conduct a study that is not covered by a protocol already contained in their IND application. |
Submission must occur prior to implementation |
Protocol Amendment – Changes to a Protocol – Eliminate Immediate Hazard |
Protocol change intended to eliminate an apparent immediate hazard to subjects |
May be implemented immediately provided FDA is subsequently notified by protocol amendment |
Protocol Amendment – Changes to a Protocol |
Any change in a Phase 1 protocol that significantly affects the safety of subjects; or Any change in a Phase 2 or 3 protocol that significantly affects the safety of subjects, the scope of the investigation, or the scientific quality of the study. |
Submission must occur prior to implementation |
Protocol Amendment – New Investigator |
When a new investigator is added to carry out a previously submitted protocol |
Notification to FDA within 30 days of the investigator being added |
Information Amendment |
Essential information on the IND that is not within the scope of a protocol amendment, IND safety reports, or annual report. |
Submitted as necessary but, to the extent feasible, not more than every 30 days |
IND Safety Report – |
Potential serious risks, from clinical trials or any other source or SUSAR (Suspected Unexpected Serious Adverse Reaction) |
No later than 15 calendar days after the sponsor determines that the information qualifies for reporting |
IND Safety Report – 7-day 4 |
Fatal or Life Threatening SUSAR |
No later than 7 calendar days after the sponsor initial receipt of the information |
IND Safety Report – |
Any relevant additional information that pertains to a previously submitted IND safety report. |
As soon as the information is available but no later than 15 calendar days after the sponsor receives the information. |
Updates on the preclinical, manufacturing and clinical (all studies under the IND) sections of the IND and to its investigational plan |
Within 60 days of the anniversary date that the IND went into effect (the “May Proceed” date). |
|
Once all protocols under the IND are ended. If the withdrawal is for safety reasons, the notification must provide a report of the reasons. |
N/A |
- 21 CFR §312.23.
- NIH Clinical Center Regulatory Toolbox (IND Maintenance).
- 21 CFR §312.30, §312.31, §312.32, §312.33, §312.38.
- Must be submitted on a MedWatch Form FDA 3500A (Form and instructions)
There are three types of full IDE maintenance submissions to the FDA: Amendments (A001, A002, etc.), Reports (R001, R002, etc.), and Supplements (S001, S002, etc.). These maintenance submissions1 are summarized in the table below and more information can be located on the FDA website IDE Reports and IDE Modifications. Please contact OCR Regulatory for additional guidance via email at PSOM-IND-IDE@POBOX.upenn.edu.
IDE Submission Type 2,3 |
Description of Submission |
Submission and/or Implementation Requirement Timeline |
---|---|---|
Amendment – Response to Disapproval |
N/A |
Response date provided in FDA communication |
Amendment – Response to Approval with Conditions |
N/A |
Response date provided in FDA communication |
Amendment – Response to Refuse to Accept |
N/A |
Response date provided in FDA communication |
Amendment – Response to Report Deficient |
N/A |
Response date provided in FDA communication |
Amendment – Voluntary Withdrawal by Sponsor |
If the IDE is not yet approved, the sponsor may request to withdraw the application |
N/A |
Report 4,5 – Unanticipated Adverse Device Effects (UADE) |
The sponsor must report the results of an evaluation of an unanticipated adverse device effect to FDA and all reviewing IRBs and investigators |
Within 10 working days after the sponsor first receives notice of the effect |
Report 4,5 – Withdrawal of IRB approval |
The sponsor must notify FDA and all reviewing IRBs and participating investigators of the withdrawal of IRB approval of an investigation (or any part of an investigation) |
Within 5 working days after receipt of the withdrawal of approval |
Report 4,5 – Deviation from the investigational plan |
Deviation does NOT affect validity of data/information; patient risk to benefit relationship; scientific soundness of plan; or rights, safety or welfare of subjects |
In progress report |
Report 4,5 – Deviation from the investigational plan |
Deviation does affect validity of data/information; patient risk to benefit relationship; scientific soundness of plan; or rights, safety, or welfare of subjects |
Within 5 working days after receipt of the notice of deviation |
Report 4,5 – Failure to Obtain Informed Consent |
Sponsors must submit a copy of any report by an investigator of the use of a device without first obtaining informed consent. |
Within 5 working days after receipt of the notice of such use |
Report 4,5 – Current Investigators List |
A current list of the names and addresses of all investigators participating in a significant risk device investigation. |
Every six months |
Report 4,5 – Annual Progress Report |
For a significant risk device, the sponsor must submit the progress report to FDA. |
At least yearly. |
Report 4,5 – Interim Progress Report |
N/A |
If requested by FDA |
Report 4,5 – Recall/Repair/Dispose Device |
The sponsor must notify FDA and all reviewing IRBs of any request that an investigator return, repair, or dispose of any unit of an investigational device. |
Within 30 working days after request is made for an investigator to return, repair, or dispose of any unit of the device |
Report 4,5 – Completion or Termination of the Investigation/Final Report |
The sponsor must notify FDA and all reviewing IRBs of the completion or termination of the investigation and submit a final report. |
Notify FDA within 30 working days of the completion or termination of the investigation Submit final report to FDA within 6 months after completion or termination |
Supplement 6 – Changes to the device or manufacturing process |
A significant change in design or any change to the basic principles of operation or Affects validity of data/information; patient risk to benefit relationship; scientific soundness of plan; or rights, safety or welfare of subjects |
FDA approval required prior to implementation |
Supplement 6 – Changes to the device or manufacturing process |
NOT a significant change in design/manufacturing or Does NOT affect validity of data/information; patient risk to benefit relationship; scientific soundness of plan; or rights, safety or welfare of subjects |
Within 5 working days of implementation |
Supplement 6 – Minor changes to the investigational plan |
If they do not affect the validity of the data, the scientific soundness of the investigational plan, or the rights, safety, or welfare of the human subjects involved in the investigation. |
In progress report |
- NIH Clinical Center Regulatory Toolbox
- FDA Guidance for Industry: Changes or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff, May 2001.
- FDA Guidance for Industry: FDA Decisions for Investigational Device Exemption Clinical Investigations, August 2014.
- FDA IDE Reports.
- 21 CFR 812.150.
- 21 CFR 812.35
Although original abbreviated IDE (aIDE) applications are not submitted to the FDA, there are some instances where FDA reporting is required as presented below. Please contact OCR Regulatory for additional guidance via email at PSOM-IND-IDE@POBOX.upenn.edu.
Required Reporting to the FDA |
Description of Submission |
Submission Timeline |
---|---|---|
Unanticipated Adverse Device Effect (UADE) |
The sponsor must report the results of an evaluation of an unanticipated adverse effect to FDA and all reviewing IRBs and investigators. |
Within 10 working days after the sponsor first receives notice of the effect |
Withdrawal of IRB Approval |
The Sponsor must notify FDA and all reviewing IRBs and participating investigators of the withdrawal of IRB approval of an investigation (or any part of an investigation). |
Within 5 working days after receipt of the withdrawal of approval |
Recall/Repair/Dispose Device |
The sponsor must notify FDA and all reviewing IRBs of any request that an investigator return, repair, or dispose of any unit of an investigational device. |
Within 30 working days of request |
Failure to Obtain Informed Consent |
The sponsor must submit a copy of any report by an investigator of the use of a device without first obtaining informed consent. |
Within 5 working days after receipt of the notice of such use |
Change in Risk by IRB |
The sponsor must submit a change in the IRB assessed risk from nonsignificant risk (NSR) to significant risk (SR). |
Within 5 working days after the sponsor first learns of the IRB's determination |